Jove
Visualize
Contact Us

Related Experiment Videos

Exenatide.

Grant M Bray1

  • 1Denver Health Medical Center, Denver, CO, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|February 18, 2006
PubMed
Summary
This summary is machine-generated.

Exenatide is an incretin mimetic for type 2 diabetes, improving glycemic control when other drugs fail. It enhances insulin secretion and is administered subcutaneously twice daily.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Sonrotoclax.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Bulevirtide Acetate-gmod.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Addressing feedback overload in pharmacy residents.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Endocrinology

Background:

  • Type 2 diabetes mellitus (T2DM) management often requires multiple agents.
  • Inadequate glycemic control persists in some patients despite metformin or sulfonylurea therapy.

Purpose of the Study:

  • To discuss the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and administration of exenatide.
  • To evaluate exenatide as an adjunctive therapy for T2DM.

Main Methods:

  • Review of exenatide's properties, including its mechanism of action as an incretin mimetic.
  • Analysis of clinical trial data on exenatide's efficacy in reducing glycosylated hemoglobin (HbA1c).
  • Documentation of pharmacokinetic parameters, adverse events, and drug interactions.

Main Results:

Related Experiment Videos

  • Exenatide significantly reduced HbA1c levels in patients with T2DM inadequately controlled by metformin and/or sulfonylureas.
  • Pharmacokinetic profile: peak plasma concentration at 2.1 hours, terminal half-life of 2.4 hours, bioavailability of 65-75%.
  • Common adverse effects include nausea, vomiting, and diarrhea; interactions with digoxin, lovastatin, lisinopril, and acetaminophen were noted.

Conclusions:

  • Exenatide is an effective incretin mimetic for improving glycemic control in T2DM.
  • It provides a novel therapeutic option for patients resistant to existing oral therapies.
  • Recommended starting dose is 5 mcg subcutaneously twice daily.